In studies analysing IMpower13310 (≥5% in tumor cells or immune cells) and CASPIAN11 (1% in tumor cells or immune cells), it was found that although SCLC with high PD-L1 expression showed a better survival in the immune checkpoint blockade group, no statistically significant differences were identified. The gene discussed is CD274; the disease is neoplasm.